These observations, together with the published results showing that Pak3 misregulation correlates with neuronal morphology defects observed in RTT [8–10, 88], strongly point at PAK3 as a putative MECP2 effector and a possible determinant of the cytoskeletal defects observed in the neurons in RTT patients’ brains. This evidence concerns the gene MECP2 and Rett syndrome.